HC Wainwright Boosts Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $30.00

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its price target boosted by HC Wainwright from $26.00 to $30.00 in a research note released on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on CPRX. Oppenheimer reaffirmed an outperform rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. Citigroup lifted their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a buy rating in a research note on Friday, August 9th. Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a buy rating in a report on Friday, August 9th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a buy rating to a strong-buy rating in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Buy and a consensus target price of $29.50.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $19.24 on Monday. Catalyst Pharmaceuticals has a 52-week low of $11.55 and a 52-week high of $19.86. The company has a 50-day simple moving average of $16.33 and a two-hundred day simple moving average of $15.70. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of 35.63 and a beta of 0.70.

Insider Buying and Selling

In other news, Director Molly Harper sold 5,333 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $16.30, for a total value of $86,927.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Catalyst Pharmaceuticals news, CEO Richard J. Daly sold 17,323 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $15.97, for a total transaction of $276,648.31. Following the completion of the sale, the chief executive officer now owns 234,824 shares of the company’s stock, valued at $3,750,139.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Molly Harper sold 5,333 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $16.30, for a total transaction of $86,927.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 146,255 shares of company stock valued at $2,441,748. 11.00% of the stock is owned by insiders.

Institutional Trading of Catalyst Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its stake in shares of Catalyst Pharmaceuticals by 2.2% during the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 654 shares during the period. Ameritas Investment Partners Inc. boosted its position in Catalyst Pharmaceuticals by 6.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 720 shares during the period. XTX Topco Ltd grew its holdings in Catalyst Pharmaceuticals by 7.5% in the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 773 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 819 shares during the period. Finally, Strategic Advocates LLC raised its stake in shares of Catalyst Pharmaceuticals by 6.5% during the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 864 shares during the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.